and being done for once at the proper time in the progression of the disease.
Thursday, May 14, 2020NIH begins clinical trial of hydroxychloroquine and azithromycin to treat COVID-19
Study enrolling adults with mild to moderate COVID-19 in the United States.
The Phase 2b trial will enroll approximately 2,000 adults at participating ACTG sites(link is external) across the United States. Study participants must have confirmed infection with SARS-CoV-2, the virus that causes COVID-19, and be experiencing fever, cough and/or shortness of breath. The investigators anticipate that many of those enrolled will be 60 years of age or older or have a comorbidity associated with developing serious complications from COVID-19, such as cardiovascular disease or diabetes. Participants will be randomly assigned to receive short-term treatment with either hydroxychloroquine and azithromycin or matching placebos.
The first participant enrolled today in San Diego, California.
The above is exactly the type of patient Zelenko is treating. Early stage of disease, and only if he considers them at risk for getting Covid complications.
Have no idea why they are leaving out zinc though, after the tremendous benefit seen in the H+A+Z vs H+A only study just out.
Feel sorry for the placebo folks, many of whom will likely die "in the name of double blind science"....